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tibiotics and it has beenhypothesized that brain damagedpatients in the intensive care unit (ICU) are particularly
at risk. The objective of this study is to determine the prevalence of subtherapeutic piperacillin concentrations in
neurocritical patients and to investigate if having a neurocritical diagnosis is a risk factor for this.Keywords:Purpose: Increased renal elimination is the leading cause for subtherapeutic concentrations of renally cleared an-
Materials and methods: Single center retrospective analysis of a prospective cohort study of adult ICU patients re-
ceiving continuous infusion piperacillin/tazobactam. Patients were categorized as either having a neurocritical
diagnosis or not. An unbound piperacillin concentration N 4× the epidemiologic cut-off value (ECOFF) of Pseudo-
monas aeruginosawas selected as the PKPD target of choice. Multivariable logistic regression was performed to
identify risk factors for subtherapeutic piperacillin concentrations.
Results: 356 patients had ameasured creatinine clearance (mCrCl) andmatched piperacillin concentration, 52 of
which had a neurocritical diagnosis. Subtherapeutic piperacillin concentrations were reported signiﬁcantlymore
frequent in neurocritical patients. Inmultivariate analysis, the only risk factor identiﬁed for subtherapeutic piper-
acillin concentration was an increasing mCrCl.
Conclusion: Subtherapeutic piperacillin concentrations are common in neurocritical patients yet having a
neurocritical admission diagnosis was not identiﬁed as an independent risk factor.
© 2019 Elsevier Inc. All rights reserved.Subtherapeutic antibiotic concentrations
Beta-lactam antibiotics
Piperacillin/tazobactam
Critically ill
Neurocritical care1. Introduction
Infection and sepsis are common in critically ill patients and are a
major cause ofmorbidity andmortality [1-3]. Early antibiotic treatment,
source control and supportive therapy are the backbone of sepsis man-
agement [4-7]. Appropriate dosing of antibiotics is vital as it is likely to
improve clinical cure and survival rates and may aid in limiting the
spread of resistance [4,8]. Because of their broad antimicrobial spectrum
and their low toxicity, beta-lactam antibiotics are frequently used as
ﬁrst line therapy in sepsis and septic shock [5].kinetics; ARC, Augmented Renal
BI, Traumatic Brain Injury; SAH,
Care Unit; APACHE II, Acute
, Extracorporeal Membrane
easured Creatinine Clearance;
nial Bleeding; iCVA, Ischemic
t-off Value; MIC, Minimum
re Medicine, Ghent UniversitySubtherapeutic beta-lactam antibiotic concentrations are a common
ﬁnding in critically ill patients [9]. Both pathogen and patient related
challenges prevent achieving therapeutic concentrations with beta-
lactam antibiotics [10]. Bacteria isolated in intensive care unit (ICU) pa-
tients in general are less susceptible tomost antibioticswhen compared
with bacteria identiﬁed in samples from non-ICU patients [10]. More-
over, a large variability in the pharmacokinetics (PK) of beta-lactam an-
tibiotics in ICU patients has been described [5,10]. Augmented renal
clearance (ARC) is assumed to be the leading cause for under dosage
of renally cleared drugs such as beta-lactam antibiotics, vancomycin or
aminoglycosides [10-12]. Other risk factors for subtherapeutic antibiotic
concentrations are higher total body weight, lower albumin levels,
younger age, lower Sequential Organ Failure Assessment (SOFA) score
and male sex [5,9].
It has been claimed that brain-damaged patients are particularly at
risk of ARC [13]. Some studies suggest an unknown cytokine inﬂuences
both, brain autoregulation and kidney autoregulation [6,14]. In patients
with traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH)
a prevalence of ARC of N80% has been described [6,15]. In addition, a re-
cent study showed that vancomycin clearance is higher in neurosurgical
patients than in the general population and neurosurgery was the only
49C. Damen et al. / Journal of Critical Care 54 (2019) 48–51identiﬁed risk factor for this higher clearance even when corrected for
risk factors for ARC [3].
The purpose of this study was to determine the prevalence of sub-
therapeutic piperacillin concentrations in patients where neurological
disease or neurotrauma was the primary reason for ICU admission.
The second aim was to explore if having a neurocritical diagnosis is an
additional risk factor for low piperacillin concentrations, independently
to the high risk of ARC in neurocritical patients.
2. Materials and methods
2.1. Study design and data collection
This was a single center retrospective analysis of a prospective col-
lected database at the department of Critical Care Medicine of Ghent
University Hospital. For this analysis, data were used from a prospective
database of patients admitted to the surgical ICU (SICU) and receiving
piperacillin/tazobactam in continuous infusion. All patients admitted
to the SICU between March 2016 and April 2018 were screened for in-
clusion. Inclusion criteria were: admission to the SICU, administration
of piperacillin/tazobactam in continuous infusion, a minimum age of
18 years old and the presence of an arterial line for sample collection.
The need for written consent was waived by the ethics committee and
blood samples were collected under opt-out sampling. This database
did not contain patients receiving extracorporeal membrane oxygena-
tion (ECMO) or renal replacement therapy (RRT) during antibiotic ther-
apy. For the purpose of this speciﬁc study, patients without a measured
creatinine clearance (mCrCl) were excluded from further analysis.
All patients received a loading dose of 4/0.5 g piperacillin/tazobac-
tam over 30 min, the standard dosing regimen was 16/2 g piperacillin/
tazobactam over 24 h and dose adaptations were made by the treating
physician and based on mCrCl: b15 mL/min, 8/1 g/24 h;
15–29 mL/min, 12/1.5 g/24 h; N30 mL/min, 16/2 g/24 h. Data collected
included demographic data (age, sex, race), biometric data (weight,
height) and disease severity scores such as the “Acute Physiology and
Chronic Health Evaluation II” (APACHE II) score upon admission and
the SOFA-score on the day of sampling. ICUmortality and hospital mor-
tality were registered.
Ethical approvalwas obtained fromGhentUniversity Hospital Ethics
Committee (Registration No. 2016/0264).
2.2. Deﬁning neurocritical diagnosis
The diagnoses at admissionwere registered in the patient dataman-
agement system (PDMS) by the treating physician. Patients were
divided into two groups for analysis: a group of patients with
neurocritical diagnosis and a control group of patients without
neurocritical diagnosis. All patients with brain damage e.g. patients
with TBI, SAH, intracranial bleeding (ICB), ischemic cerebrovascular ac-
cident (iCVA), status epilepticus, subdural hematoma, meningitis/en-
cephalitis, brain edema, hydrocephalus and skull fractures were
categorized as neurocritical patients.
2.3. Deﬁning augmented renal clearance
ARC is deﬁned as a clearance of N130mL/min [10,16] and severe ARC
as a clearance of N200 mL/min. An 8-hourly urinary collection using an
indwelling urinary catheter was used to calculate the measured creati-
nine clearance. In critically ill patients, the mCrCl in the same patients
may vary signiﬁcantly over time [6,17]. If multiple samples were avail-
able for one patient, the sample with the highest mCrCl was selected
for analysis as well as the antibiotic concentration and SOFA-score on
the same day. The highest mCrCl was chosen to avoid missing subther-
apeutic concentrations as increased renal clearance is themajor risk fac-
tor for subtherapeutic beta-lactam concentrations [10-12].2.4. Antibiotic target concentrations
Blood samples were collected during the daily morning routine to
build the prospective database used for this study. A residual sample
of the 3-mL blood gas syringes (RAPIDLyte; Siemens Healthcare Diag-
nostics Deerﬁeld, IL, USA) was sent to the laboratory where they were
stored at 4 °C until further processing [18]. Within 24 h, samples were
transferred to a 1.5-mL Eppendorf tube, and centrifuged at 16162 xg
for 8min (Beckman Coulter, Brea, CA, USA) [18]. Immediately after cen-
trifugation, plasma was collected and stored at−80 °C until analysis,
which was performed within 3 months [18]. The plasma concentration
of piperacillin was determined by ultrahigh performance liquid chro-
matography coupled with tandem mass spectrometry [19]. The lower
limit of quantiﬁcation for piperacillin was 1.5 mg/L [19].
An unbound antibiotic concentration of N4 x the epidemiologic cut-
off value (ECOFF) was selected as the target of choice because this con-
centration is associated with maximal bacterial killing and a positive
clinical outcome [5,20]. For piperacillin, the ECOFF and clinical
breakpoint for Pseudomonas aeruginosa is 16 mg/L [21]. Because un-
bound piperacillin concentrationswere not measured and an estimated
20% of piperacillin is bound to albumin, a measured total piperacillin
concentrations b80 mg/L was considered as subtherapeutic [22].
2.5. Statistical analysis
Results were expressed as median and interquartile range for con-
tinuous variables unless otherwise stated, and as numbers and percent-
ages for categorical variables. Comparison between continuous
variables was done with the unpaired t-test or Mann-Whitney U test
as appropriate and comparison between categorical variables was
donewith the Chi-square test.Multivariable logistic regressionwas per-
formed to assess the inﬂuence of the variable risk factors on piperacillin
plasma concentrations. For the regression, the following variables were
included as predictor of low piperacillin concentrations: mCrCl, body
weight, plasma albumin, sex, age and SOFA-score [4,5,9,23]. No collin-
earity was found between these risk factors as assessed by the variance
inﬂation factor (VIF). All tests were two-tailed and a p-value b.05 was
considered statistically signiﬁcant. Statistical analysis was performed
using the R language and software environment for statistical computa-
tion, version 3.5.0. [R Development Core Team (2018), Vienna, Austria.
URL: http://www.R-project.org], the software package R studio, version
1.1.456 [RStudio Team (2016). Boston, USA. URL: http://www.rstudio.
com] and the software packages car [https://CRAN.R-project.org/
package=car] and generalhoslem [https://CRAN.R-project.org/
package=generalhoslem].
3. Results
3.1. Demographic data
In total, 395 patients received piperacillin in continuous infusion and
for 356uniquepatients, amCrCl andmatchedpiperacillin concentration
were available. Seventy ﬁve sampleswere collected the ﬁrst day of ther-
apy (between 0 and 24 h after starting piperacillin), 125 samples were
collected the second day of therapy (between 24 and 48 h). One hun-
dred ﬁfty-six samples were collected after 48 h of therapy. Fifty-two pa-
tients had a neurocritical diagnosis of which 25 were admitted with
(poly)neurotrauma, 11 with SAH, 10 ICB, 2 with iCVA, 1 with subdural
hematoma, 1 with hydrocephalus, 1 with metabolic encephalopathy
due to hyponatremia and 1 status epilepticus. The other 304 patients
had various diagnoses but not a single neurocritical one: 177 patients
were admitted with a surgical diagnosis, 120 with a medical diagnosis
and 7 were trauma patients without traumatic brain injury.
Baseline demographic data are presented in Table 1. In univariate
analysis, patientswith a neurocritical diagnosiswere signiﬁcantly youn-
ger, had a signiﬁcantly higher APACHE II score and had a signiﬁcantly
Table 1
Demographic data of patients with a neurocritical diagnosis and patients with a non-
neurocritical diagnosis.
TOTAL Neurocritical Other diagnosis p-Value
N = 356 N = 52 N = 304
Age (years) 54.5 (41.50 – 63.25) 66.0 (55.0 – 74.0) b0.001
Male sex 30 (57.7%) 207 (68.1%) 0.14
Weight (kg) 74.6 (13.0)⁎ 75.7 (18.3)⁎ 0.62
Heigth (cm) 172 (10.4)⁎ 171 (9.5)⁎ 0.52
BMI (kg/m2) 25.0 (3.9)⁎ 25.6 (5.9)⁎ 0.38
APACHE II 23.0 (20.8 – 26.0) 19.0 (15.0 – 26.0) 0.024
SOFA-score 6.0 (2.5 – 9.0) 5.0 (3.0 – 8.0) 0.45
Plasma creatinine (mg/dL) 0.62 (0.54 – 0.71) 0.77 (0.52 – 1.24) b0.001
mCrCl (ml/min) 173 (121 - 208) 99 (56 - 153) b0.001
Patients with ARC 36 (69.2%) 113 (37.2%) b0.001
Patients with severe ARC 17 (32.7%) 32 (10.5%) b0.001
Albumin (g/dL) 27.5 (3.8)⁎ 23.6 (4.4)⁎ b0.001
Hospital mortality 12 (23,1%) 64 (21,1%) 0.74
Bold indicates statistically signiﬁcant results.
⁎ Mean (standard deviation).
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diagnose. Also, mCrCl was signiﬁcantly higher in neurocritical patients
and signiﬁcantly more ARC and severe ARC was observed in the
neurocritical group. Sex, weight, height, APACHE II, SOFA-score on the
day of sampling and mortality were similar in both groups.
3.2. Subtherapeutic piperacillin concentrations
The prevalence of subtherapeutic piperacillin concentration was
51.4% (183/304); the median piperacillin concentration was 78.1 mg/L
(IQR 52.2–126.1 mg/L). In univariable analysis, subtherapeutic pipera-
cillin concentrations were more frequent in the group consisting of
patients with a neurocritical diagnosis compared to patients with a
non-neurocritical diagnosis (83% (43/52) vs. 46% (140/304), p b .001).
In neurocritical patients, the median piperacillin concentration was
41.8 mg/L (IQR 31.1–70.7 mg/L) whereas in non-neurocritical patients
it was 85.7 mg/L (IQR 58.0–134.5 mg/L, p b .001).
3.3. Risk factors for subtherapeutic piperacillin concentration in critically ill
patients
Multivariate logistic regression analysis showed that having a
neurocritical admission diagnosiswas not associatedwith subtherapeu-
tic piperacillin concentrations. The only risk factor identiﬁed for sub-
therapeutic piperacillin concentrations was mCrCl (p b .001). Body
weight, sex, age, SOFA-score and albuminwere not identiﬁed as risk fac-
tors for subtherapeutic piperacillin concentrations (Table 2). The
goodness-of-ﬁt-test was done with Hosmer-Lemeshow and the
p-value was 0.66.
4. Discussion
This study demonstrated a high prevalence of subtherapeutic piper-
acillin concentrations in patients with a neurocritical diagnosis, admit-
ted to the SICU. Nevertheless, having a neurocritical admissionTable 2
Risk factors for subtherapeutic piperacillin concentrations in the critically ill using multi-
variable logistic regression.
Characteristic OR 95%-CI p-Value
Neurocritical diagnosis 2.28 0.89–6.27 0.095
mCrCl 1.03 1.02–1.03 b0.001
Body Weight 1.02 1.00–1.04 0.067
Male Sex 1.40 0.73–2.72 0.31
Age 0.98 0.97–1.00 0.13
SOFA-score 0.96 0.89–1.03 0.21
Albumin 1.03 0.97–1.10 0.32diagnosis was not found as an independent risk factor for subtherapeu-
tic piperacillin concentrations. The only risk factor for subtherapeutic pi-
peracillin concentrations identiﬁed in multivariable logistic regression
was a higher mCrCl.
Recognizing patients at risk of subtherapeutic antibiotic concentra-
tions is important as it may lead to antibiotic failure and aworse clinical
outcome [4,24]. Having a neurocritical diagnosis has been linked to ARC
and inadequate antibiotic concentrations in the past [13]. However, in
this study we found that neurocritical diagnosis was not associated
with subtherapeutic piperacillin concentrations. The presence of sepsis
in a younger ICU patient should trigger the treating physician to obtain
amCrCl and consider the probability of subtherapeutic piperacillin con-
centrations, independently of the admission diagnosis.
The prevalence of subtherapeutic piperacillin concentrations is re-
ported inconsistently in the literature, mainly due to the different de-
signs of these studies (i.e. different antibiotic targets and modes of
administration). For example, Aardema et al. [22] found that in the
maintenance phase 57.6% of samples were below the target concentra-
tion of 80mg/L. This is little higher than the prevalence of subtherapeu-
tic piperacillin concentrations we found, but they used a standard
dosing regimen of 12/1.5 g piperacillin tazobactam in continuous infu-
sion after a loading dose of 4/0.5 g piperacillin tazobactam, which is
lower than the dosing regimen we used [22]. Carrié et al. [26] used
16/2 g piperacillin tazobactam in continuous infusion as standard dos-
ing regimen. They found that 19% of critically ill patients had subthera-
peutic piperacillin concentrations, but the target concentration in this
study was lower (16 mg/L) [26].
Another more recent study concluded that the vancomycin clear-
ance is higher in neurosurgical patients compared with others even
when corrected for risk factors for ARC [3]. This ﬁnding is potentially
in line with our ﬁndings, because the study corrected only for risk
factors for ARC and not for mCrCl. In this study mCrCl was used as
a continuous variable because dichotomizing confounding variables
(i.e. ARC yes or no) may result in an inﬂation of the type-I error
rate [25].
The prevalence of ARC found in this study was lower than the prev-
alence described in previous studies of neurocritical subgroups
[1,6,14,15]. A possible reason why we found a lower prevalence of
ARC than previous studies is because instead of studying speciﬁc sub-
groups (such as patients with SAH or TBI), a mixed neurocritical popu-
lation was studied.
This study has a number of limitations. First, no information about
the organisms and MICs were available for analysis and it is therefore
possible that the number of patients with subtherapeutic piperacillin
concentrations were overestimated as the ECOFF (16 mg/L) of Pseudo-
monas aeruginosa was used to calculate target attainment. Also, only
the unbound fraction of a drug at the site of infection is able to exert
its antimicrobial effect [10]. As tissue perfusion in ICU patients may be
highly variable, therapeutic plasma concentrations may not necessarily
lead to therapeutic infections site concentrations [10].
Predicting antibiotic target attainment in critically ill patients is chal-
lenging as a lot of patient speciﬁc factors inﬂuence antibiotic concentra-
tions. It is important to keep investigating which patient factors
inﬂuence antibiotic target non-attainment and to explore the underly-
ing pathophysiological mechanisms. By doing so, dosing regimens that
are more tailored to patient-speciﬁc factors may be used in the future.5. Conclusion
Subtherapeutic piperacillin concentrations in patients admitted to
the SICU with a neurocritical diagnosis are common. Nevertheless, we
were unable to demonstrate that having a neurocritical admission diag-
nosis is an independent risk factor for subtherapeutic piperacillin con-
centrations. The only risk factor tied to subtherapeutic piperacillin
concentrations was a higher measured creatinine clearance.
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